Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

CR Sanjiu Buys 28% of Tasly Pharma for $869 Million

publication date: Aug 5, 2024

China Resources Sanjiu Medical & Pharmaceutical will buy a 28% stake in Tianjin’s Tasly Pharma Group for $869 million. Both companies make traditional Chinese medicines and pharmaceutical products, but Tasly also develops biologic medications through a subsidiary, Tasly Biopharma. Although CR Sanjiu will own only 28% of Tasly, the company said it would become Tasly’s controlling shareholder. Tasly Great Health will also transfer 5% of Tasly’s shares to CR Sanjiu's major shareholder, Guoxin Investment. CR Sanjiu is one of many companies that are a part of China Resources Corporation, a state-owned entity. More details....

Share this with colleagues:  



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here